Gaia Lands Major Credit Line to Bring AI-Backed IVF Financing to More Americans
NEW YORK – Gaia, the fertility financing platform that bundles AI-driven treatment planning with outcome-based financial protection, has secured a $100 million debt facility from Viola Credit to accelerate its U.S. expansion. The announcement follows a $14 million Series A round in January 2025 led by Valar Ventures, bringing Gaia’s total equity funding to $37 million across three rounds.
The numbers behind the fertility care gap are hard to argue with. A single in vitro fertilization (IVF) cycle in the United States typically runs between $15,000 and $25,000, with per-cycle success rates hovering between 25% and 40% – meaning many patients face multiple rounds and cumulative costs that can exceed $100,000.
Only 27% of U.S. employers offer fertility benefits, and those benefits are typically capped between $10,000 and $20,000 lifetime, often not enough to cover even a single complete treatment journey. Three out of four people who seek fertility treatment never start it, primarily because of financial barriers.
Gaia’s model was built specifically to fill that gap.
Rather than offering a loan or a standard repayment plan, the company uses an AI system called Gabi, trained on 1.6 million IVF cycles, to forecast the number of treatment rounds a patient is likely to need, steer them toward the most clinically appropriate clinics, and price their plan accordingly. If a cycle is cancelled before retrieval or produces no viable embryos, patients receive refunds or credits, depending on their plan type. The company describes its core product as “outcome protection” rather than insurance.
Gaia currently operates across 57 U.S. clinic locations through 23 clinic groups, having initially launched in London in 2022. Its U.S. clinical partnerships include IVI RMA North America, one of the largest assisted reproduction networks on the continent, which signed on in 2025 as part of a broader push into value-based fertility care. The new debt facility is intended to fund additional patient cycles directly, meaning the capital doesn’t go toward corporate overhead, but is deployed into the actual cost of treatment on the front end, with repayment triggered by outcomes.
That structure matters for how the fertility financing space gets evaluated.
Last year, venture investors directed roughly $194.8 million toward fertility-related startups globally – a sector that has never quite found its footing as a venture category despite persistent demand. A debt facility of this scale, tied directly to treatment volume, represents a different kind of institutional confidence: not in a technology product, but in a financial model that only earns returns when patients succeed.
Predictive AI in medicine has a long record of performing well in controlled datasets and less uniformly in clinical practice. And with fertility outcomes shaped by age, biology, and variables that no algorithm fully captures, the gap between a 90% accuracy claim in forecasting and the lived experience of a patient mid-treatment can be significant.
Still, the access problem Gaia is trying to solve is real, well-documented, and largely untouched by conventional insurance or employer benefits. If the company’s financial architecture delivers on its premise at scale, it would represent one of the more concrete applications of AI in healthcare, not diagnosing disease or generating clinical notes, but changing who can afford to try.
DISCLAIMER: WellnessFN covers the business and science of health and wellness. This article is for informational purposes only and does not constitute medical or financial advice.
